Optimizerx Corporation ((OPRX)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Optimizerx Corporation’s latest earnings call painted a mixed picture for investors, combining solid margin gains and product traction with clear revenue headwinds. Management stressed that pressures on the top line, including a 10% year-over-year decline and lower contracted revenue, should be temporary, while cost discipline and digital platform initiatives lay groundwork for a recovery toward 2027.
Q1 Revenue Beat Despite 10% Year-Over-Year Decline
OptimizeRx reported Q1 revenue of $19.8 million, down from $21.9 million a year earlier as low-margin managed services dropped out. Even with this 10% decline, the company said it exceeded consensus expectations on both revenue and earnings, underscoring resilience in its core business amid a tougher demand backdrop.
Adjusted EBITDA Surges on Operating Leverage
Adjusted EBITDA more than doubled to $3.3 million from $1.5 million in the prior-year period, an increase of roughly 120%. Management credited improved operating leverage and disciplined cost management, signaling that profitability is scaling even as the company works through near-term revenue challenges.
Non-GAAP Profitability Improves as GAAP Loss Narrows
Non-GAAP net income rose to $2.7 million, or $0.14 per diluted share, up from $1.5 million or $0.08 a year ago, an increase of about 80%. The GAAP net loss shrank significantly to $0.5 million from $2.2 million, showing steady progress toward sustainable profitability under standard accounting.
AI-Driven DAP Platform Shows Strong Momentum
The company’s AI-enabled DAP solution remained a bright spot, growing 60% year-over-year in Q1 and validating its product-market fit. DAP subscription revenue climbed 45%, increasing the share of recurring revenue and enhancing visibility, which management views as a key pillar of long-term growth.
Gross Margins Rise as Expenses Fall
OptimizeRx now expects full-year gross margin to land in the high-60% range, supported by a richer mix of higher-margin offerings. Total expenses fell by $4.6 million year-over-year, and management targets about $3 million of annualized cash operating expense reductions, including roughly $1 million of benefit in 2026.
KPIs Highlight Solid Retention and Productivity
Net revenue retention held at a healthy 110%, signaling that existing clients are spending more despite industry volatility. Revenue per full-time employee increased to $801,000 from $710,000, while average revenue per top-20 pharmaceutical customer reached $2.8 million, with these large clients contributing 52% of Q1 sales.
Refinancing Strengthens Balance Sheet Flexibility
The company refinanced its debt with a fully drawn $25 million term loan from Fifth Third Bank and access to a $10 million revolver. This move is expected to deliver roughly $1.5 million in annual interest savings, giving OptimizeRx more flexibility to navigate the current revenue slowdown and invest in growth initiatives.
Programmatic and DSP Access as Long-Term Growth Driver
Management emphasized the opportunity in programmatic media, enabling demand-side platforms that control more than 80% of digital promotion budgets to tap into its EHR network. With less than 10% of network inventory currently utilized, optimizing DSP access could unlock a significant long-term growth channel as adoption ramps into 2027.
Revenue Decline Reflects Mix Shift and Macro Caution
The 10% year-over-year revenue decline reflects reduced low-margin managed services, which weighed on the top line even as margins improved. Management also pointed to MFN-related budget caution, shorter contract durations, and other macro factors as reasons for slower growth in the near term.
Contracted Revenue and Visibility Under Pressure
Contracted revenue remained about 15% to 20% below the prior year, excluding managed services, undermining visibility into full-year performance. Shorter contract terms and MFN-related disruptions mean the company has less line of sight into future bookings, prompting a more cautious outlook on sales ramp timing.
Major Client Disruption and Execution Missteps
One large client is experiencing ongoing disruption that is partly tied to MFN dynamics and partly to execution issues on OptimizeRx’s side. This single relationship has materially affected near-term growth prospects and contributed to the company’s conservative stance on revenue guidance for the rest of the year.
Cash Position Softens Amid Negative Operating Cash Flow
Operating cash flow was negative $0.5 million in Q1, largely because of bonus and commission payouts, highlighting some pressure on cash generation. The cash balance fell to $20.2 million from $23.4 million at year-end, while debt stood at $23.6 million, though the company did pay down $2.7 million of principal.
Managed Services Exit Weighs on Near-Term Sales
OptimizeRx reported no DTC managed services revenue in the quarter, removing a source of low-margin business from the mix. While this choice supports higher gross margins, it also reduces near-term revenue, magnifying the impact of other demand and contract-related headwinds.
Customer Concentration Remains a Key Risk Factor
The top-20 pharmaceutical manufacturers represented 52% of Q1 revenue, underscoring meaningful customer concentration. Any shifts in budget behavior, renewals, or strategic priorities at these large accounts could significantly influence the company’s revenue trajectory over the next few quarters.
Guidance Points to Margin Strength Amid Top-Line Caution
For full-year 2026, OptimizeRx cut its revenue outlook to $95 million to $100 million and flagged lower visibility, but it maintained adjusted EBITDA guidance of $21 million to $25 million and gross margins in the high-60% range. Management expects about 60% of revenue to fall in the second half and sees expense savings plus programmatic and DAP growth as key levers for recovery.
Investors are left weighing a company that is clearly tightening its margin profile and growing high-value products against real revenue softness and concentrated client risk. If OptimizeRx executes on its DSP strategy and stabilizes key accounts, the groundwork laid today could translate into meaningful upside, but near-term performance will likely hinge on bookings and visibility improving through 2026.